The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
about
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancerCancer and the blood-brain barrier: 'Trojan horses' for courses?Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosisCD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasCharacterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastasesEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerCell-culture models of the blood-brain barrierSignificance and therapeutic value of miRNAs in embryonal neural tumorsDevelopmental and pathological angiogenesis in the central nervous systemA carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brainTargeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brainTargeted Therapies for Brain Metastases from Breast CancerPerillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain MetastasesMicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknownHyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier[Quality of life after prophylactic cranial irradiation in locally advanced non-small-cell lung cancer].Therapeutic strategies to improve drug delivery across the blood-brain barrier.Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of gliomaShort-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.Metastasis: a therapeutic target for cancer.Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.Targeted drug delivery across the blood-brain barrier using ultrasound technique.Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery.Recent advances in blood-brain barrier disruption as a CNS delivery strategy.Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin.Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme.Novel Peripherally Derived Neural-Like Stem Cells as Therapeutic Carriers for Treating Glioblastomas.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain CancersCurcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.Synthesis and in vitro evaluation of BBB permeability, tumor cell uptake, and cytotoxicity of a series of carboranylporphyrin conjugates"A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies".Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.Preclinical profile of cabazitaxel.
P2860
Q24621947-8BE77389-C47B-431F-810C-C8DFC8DEFC4AQ24649731-AACC00F1-D868-4B57-B206-44CEFAE686DDQ24649780-0EF94223-731F-410F-8993-A3E6CA0D0951Q24651212-E7A4C82D-CD30-45C9-A440-83833DD74618Q26740520-01F54E5A-D439-4F37-AA48-E60881D0B2BCQ26750508-5A411772-0867-4D6D-B580-B2AECE23F2A1Q26824799-9CBC30E5-D3E5-4831-95A3-5AD5CDBD92DDQ26827093-772F97EA-AC11-44EE-A7D2-3EBF8E2623F7Q26827171-96AD5EC5-54E9-4DF6-A37A-F52F164573F4Q27023250-823662B5-849C-41C4-8AEB-6367BCB4AAAAQ27311201-AB8F533E-E979-4CA3-8D4C-60B781A03E0FQ27316967-2E9FBB42-5573-4477-A631-9D7FBEEE81FEQ27331875-6CC10654-5572-4A8C-B7E7-ECD4CAF4781BQ28068154-7CAF48BE-0705-487A-BC64-FB28BFC2EC4EQ28072442-48ECAACF-A843-4CE8-B7C7-45113F6065A1Q28083277-B31B2EFD-9E17-46FB-9D4F-008F900E91EAQ28550363-0DBCBB4A-B9C3-4211-8D66-5885D557C2E7Q30318172-0EBA00B5-FD19-4118-875B-6BEE187B426DQ30407443-96CA8D69-70DF-47C8-934F-8F2E68D9EBCDQ30413487-2B9E7AF0-5CC6-47EA-8D7F-08D77764F1DAQ30429246-54F42066-5195-45D5-890B-A1C3231EA3EFQ30439221-75A0B643-F728-46AB-94BE-F7519A2DE46EQ30452421-59A4BBEC-B3E0-43D9-94CB-D264F4582474Q30474781-1DE1945B-5595-41DD-AD32-4269BC6AD379Q31114235-E13C084E-378F-4885-A490-E31EDB62E405Q31154008-8C9C6A31-7EA4-443A-8B8E-66EFA4E409EAQ33361310-4BE4987F-C460-4E3D-A38B-9E4B0A0D5BD6Q33416019-61C722B7-CD0E-421D-8475-E200E19CB351Q33722528-B68C3CFE-06D9-42F6-9E1E-5EA5E57B8C19Q33729396-2E69B55B-1E56-48D1-BFAF-6579D9BE64CDQ33760569-4838E896-4DEB-4773-8A20-3D7E9845DE26Q33822099-310DCC32-D172-4AB4-AC9F-8B2CAF9ED000Q33875921-DEAD0F0B-6BDB-4B87-865C-61793B10483BQ33909294-B1121956-EF75-490D-AD42-FAF6320C0630Q34061191-D7477107-58F2-4E2C-A178-0EAEEDEF7C18Q34122934-C6FFF3BF-83AC-49F5-9311-DF4CE888F0F1Q34132872-3C0B68EF-8DD5-45F6-A00D-85246F75B3C8Q34293696-A7C1195B-CD10-4442-AE64-2C243F7FB975Q34393640-5121ECA7-6F62-486B-8B57-479A1E97656AQ34394251-825C8CDF-DF00-4E41-B148-7F1EEBD2431F
P2860
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@ast
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@en
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@nl
type
label
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@ast
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@en
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@nl
prefLabel
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@ast
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@en
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@nl
P1476
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.
@en
P2093
John F Deeken
Wolfgang Löscher
P304
P356
10.1158/1078-0432.CCR-06-2854
P407
P577
2007-03-01T00:00:00Z